Is Centessa Pharmaceuticals plc (CNTA) Halal?

NASDAQ Healthcare United Kingdom $4.2B
✓ HALAL
Confidence: 95/100
Centessa Pharmaceuticals plc (CNTA) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 3.1% against the AAOIFI threshold of 30%, Centessa Pharmaceuticals plc comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Biotechnology), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 3.1%
/ 30%
12.6%
/ 30%
1.2%
/ 30%
N/A ✓ HALAL
DJIM 3.1%
/ 33%
12.6%
/ 33%
1.2%
/ 33%
N/A ✓ HALAL
MSCI 20.3%
/ 33%
83.6%
/ 33%
7.9%
/ 33%
N/A ✗ NOT HALAL
S&P 3.1%
/ 33%
12.6%
/ 33%
1.2%
/ 33%
N/A ✓ HALAL
FTSE 20.3%
/ 33%
83.6%
/ 33%
7.9%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-1.89
P/B Ratio
12.8
EV/EBITDA
-17.5
EV: $3.7B
Revenue
$0
Beta
1.6
High volatility
Current Ratio
10.6

Profitability

Gross Margin 100.0%
Operating Margin -1425.3%
Net Margin 0.0%
Return on Equity (ROE) -60.6%
Return on Assets (ROA) -25.3%

Cash Flow & Balance Sheet

Operating Cash Flow-$142M
Free Cash Flow-$142M
Total Debt$117M
Debt-to-Equity39.2
Current Ratio10.6
Total Assets$577M

Price & Trading

Last Close$29.40
50-Day MA$25.80
200-Day MA$22.09
Avg Volume1.3M
Beta1.6
52-Week Range
$9.60
$30.58

About Centessa Pharmaceuticals plc (CNTA)

CEO
Dr. Mario Alberto Accardi Ph.D.
Employees
114
Sector
Healthcare
Industry
Biotechnology
Country
United Kingdom
Exchange
NASDAQ
Market Cap
$4.2B
Currency
USD

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Centessa Pharmaceuticals plc (CNTA) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Centessa Pharmaceuticals plc is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Centessa Pharmaceuticals plc's debt ratio?

Centessa Pharmaceuticals plc's debt ratio is 3.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 20.3%.

What are Centessa Pharmaceuticals plc's key financial metrics?

Centessa Pharmaceuticals plc has a market capitalization of $4.2B. Return on equity stands at -60.6%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.